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Abstract
Background and purpose Radiation-esophagitis and weight
loss are frequently observed toxicities in patients treated with
concurrent chemo-radiotherapy (CT-RT) for non-small cell
lung cancer (NSCLC) and might be related. The purpose
was to investigate whether weight loss already starts early
after initiation of CT-RT and precedes radiation-esophagitis.
Materials and methods In a retrospective cohort, weight and
esophagitis grade ≥2 were assessed during the first weeks of
(CT-)RT in patients treated with concurrent (n=102) or se-
quential (n=92) therapy. In a prospective validation study,
data on body weight, esophagitis grade ≥2, nutritional intake
and muscle strength were obtained before, during and follow-
ing CT-RT.
Results In the retrospective cohort, early weight loss was ob-
served in concurrently treated patients (p=0.002), independent
of esophagitis≥grade 2. Early weight loss was also observed in
the prospective cohort (p=0.003) and was not accompanied by
decreases in nutritional intake. In addition lower limb muscle
strength rapidly declined (p=0.042). In the later weeks of
treatment, further body weight loss occurred (p<0.001) despite
increased nutritional supplementation and body weight was
only partly recovered after 4 weeks post CT-RT (p=0.003).
Conclusions Weight loss during concurrent CT-RT for
NSCLC starts early and prior to onset of esophagitis, requiring
timely and intense nutritional rehabilitation.
Keywords Weight loss . Chemotherapy . Concurrent .
Esophagitis . Non-small cell lung cancer . Radiotherapy
1 Introduction
Concurrent administration of chemotherapy and radiotherapy
(CT-RT) is the treatment of choice for many patients with
locally advanced non-small cell lung cancer (NSCLC). It has
been demonstrated that this intensive multimodal treatment
regimen results in significantly longer disease free and overall
survival [1, 9, 10, 18]. However, concurrent administration of
CT-RT is associated with a higher incidence of severe
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esophagitis [11, 17]. Therefore, according to current treatment
guidelines, only patients with minimal comorbidity and with a
good performance status are considered eligible for concurrent
CT-RT [5].
Concurrent CT-RT in NSCLC generally consists of one
induction cycle of chemotherapy, which is followed by a 5-
week period of concurrent CT-RT. Acute esophagitis develops
during the administration of RT. Patients experience dyspha-
gia, which continues to get worse up to 2 weeks after the end
of CT-RT, with healing within 4–8 weeks. Severe (grade 3 or
more) dysphagia is observed in about 25 % of patients treated
with concurrent CT-RT and when taken any grade into ac-
count, over 80 % experience difficulties in swallowing [6].
Intuitively, the frequently observed body weight loss during
concurrent CT-RT is a result of impaired dietary intake due to
dysphagia [24]. However, alternatively, induction of systemic
metabolic alterations by the intense treatment regimen could
deplete body mass by altering neuroendocrine regulation of
dietary intake and/or wasting of fat and muscle body compart-
ments [12]. Because these alternative mechanisms might re-
quire different (co)interventions, the exact time course and
etiology of body weight loss during CT-RT should be identi-
fied to optimize patient care [20, 21].
Based on clinical observations, we hypothesized that body
weight loss starts early after initiation of therapy and precedes
the presence of esophagitis. Since no published data on this
clinically relevant problem is to the best of our knowledge
available, we assessed weekly body weight changes during
concurrent and sequential CT-RT for NSCLC and correlated
this with esophagitis scores in a retrospective cohort. The
findings in the retrospective cohort were validated in a pro-
spective study design, in which body weight and esophagitis
scores were assessed over a longer time period, i.e. prior,
during and following concurrent CT-RT for NSCLC, and
additional data on nutritional intake, muscle strength and
quality of life was collected.
2 Patients and methods
2.1 Study population
Outcome parameters were determined in a retrospective co-
hort and prospective study (Fig. 1). A schematic representa-
tion of the study points in the retrospective cohort is depicted
in Fig. 2a and of the prospective study in Fig. 2b. Please see
the supplementary data for details on inclusion criteria, study
population characteristics and ethical guidelines of the study.
2.2 Chemotherapy
Chemotherapy was administered according to national and
international guidelines. Generally, patients received one or
more cycles of induction therapy followed by RT alone, i.e.
sequential CT-RT, or RT in combination with CT, i.e. concur-
rent CT-RT. Please see Table 2 for an overview of the respec-
tive CT types used. Standard dose reduction rules were ap-
plied for all CT schemes if indicated. Cycles were repeated
every 21 days.
2.3 Radiotherapy
RT techniques have been described previously [7, 22]. Please
see the supplementary data for a short description. Patients in
both the retrospective and prospective cohort treated with
concurrent CT-RT received on the same target volumes first
45 Gy, delivered in twice-daily fractions of 1.5 Gy with at
least 8 h of inter-fraction interval, followed by once-daily
fractions of 2 Gy until a pre-defined normal tissue constraint
was reached, being a mean lung dose (MLD) of 19±1 Gy or a
spinal cord maximal dose of 54 Gy. The maximal allowed
dose was 71 Gy. Patients treated with sequential therapy
received twice-daily 1.8 Gy until the normal tissue constraints
reported in the supplementary data were reached.
2.4 Toxicity scoring
Toxicity of treatment was assessed by a radiation oncologist
using the Common Terminology Criteria for Adverse Events
version 3.0 (CTCAEv3.0). According to the CTCAEv3.0,
treatment-induced dysphagia and esophagitis are almost sim-
ilar. For consistency, the problems with swallowing and die-
tary intake associated with concurrent or sequential CT-RTare
referred to as esophagitis. According to the CTCAEv3.0,
esophagitis causes changes in dietary intake from grade 2
on. In order to study effects of esophagitis on dietary intake,
esophagitis scores were therefore further referred to as grade
<2 or ≥2. Esophagitis scores were collected at the time points
depicted in Fig. 2.
2.5 Nutritional intake
In the prospective study, dietary intake was calculated using a
24 h dietary recall assessment at the time points indicated in
Fig. 2b. Energy and macronutrient intake were calculated
according to Netherlands Nutrition Centre guidelines (www.
voedingscentrum.nl).
2.6 Muscle strength
In the prospective study, hand and quadriceps muscle strength
was assessed at the time points indicated in Fig. 2b (when
physical condition of patients allowed it). Hand muscle
strength was assessed using a hand grip meter. Isometric and
isokinetic strength of quadriceps muscle was measured by
Biodex dynamometer (Biodex system version 3.3). Please
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see the supplementary data for a description of the muscle
strength assessment procedure.
2.7 Quality of life
For the evaluation of the quality of life in patients in the
prospective cohort, the European Organisation for Research
and Treatment of Cancer (EORTC) quality of life question-
naire C30 (QLQ-C30) was used. Data on quality of life was
obtained at the time points indicated in Fig. 2b.
2.8 Statistical analysis
Data was analysed using SPSS version 15.0. For descriptive
statistics, results are expressed as means±standard deviation
(SD). P values lower than 0.05 were considered statistically
significant.
In the retrospective cohort, continuous variables were
compared using an independent samples T test. The Pearson
chi-square testwas used for comparing categorical variables.
Associations between body mass index (BMI; body weight
corrected for height) changesduringconcurrent or sequential
CT-RT and a number of clinical and treatment parameters
(age, gender, World Health Organization (WHO) perfor-
mance status, Charlson comorbidity index [3], smoking in-
cidence, duration of CT-RT (in weeks), mean lung dose
(MLD), mean esophageal dose (MED), maximum spinal
cord dose and grade esophagitis ≥2) were analysed with
longitudinal data analysis bymeans of a linear mixed regres-
sion model.
Fig. 1 Flowchart of inclusion in
retrospective and prospective
analysis
Fig. 2 a Schematic
representation of study points in
retrospective cohort. b Schematic
representation of study points in
prospective cohort
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In the prospective data, paired sample T test was used for
statistical analysis for outcome parameter comparison be-
tween specific time points.
3 Results
3.1 Retrospective cohort
3.1.1 Study population characteristics
Baseline characteristics of the study population are shown in
Table 1. No differences were observed between patients treat-
ed with sequential and concurrent CT-RT with respect to
gender, height, body weight at diagnosis or at start of (CT)-
RT, histology, TNM stage, Charlson Comorbidity Index and
smoking incidence, whereas the mean age of patients treated
with concurrent CT-RTwas significantly lower than the age of
sequentially treated patients (p=0.001).
3.1.2 Treatment characteristics
Treatment characteristics are depicted in Table 2. Patients
treated with concurrent CT-RT received one or two cycles of
induction CT in 84.7 % of the cases. Induction CT in this
group consisted in 82.2 % of cases of carboplatin or cisplatin
combined with gemcitabine. The majority of patients (84.7 %)
of concurrently treated patients received two cycles of
cisplatin-based concurrent CT, combined with either vinorel-
bine or etoposide. Patients treated with sequential CT-RT
received three cycles of induction CT in 89.8 % of cases. This
induction chemotherapy consisted in 84.7 % of patients of
carboplatin or cisplatin combined with gemcitabine (Table 2).
The total radiation dose was 61.4±6.7 Gy (range 45–
69 Gy) in the concurrent group and 59.2±10.8 Gy (range
20–79 Gy) in sequentially treated patients, which was not
significantly different (Table 2). Also, the mean lung, mean
esophagus and maximal spinal cord dose did not differ be-
tween the two groups (Table 2).
3.1.3 Body weight loss during concurrent and sequential
CT-RT
A significantly higher number of sequentially than concur-
rently treated patients showed a decrease in body weight
during the period between diagnosis and start of (CT-)RT,
which represents the induction chemotherapy period (p=
0.012; Table 3). However, the mean loss of body weight
during induction chemotherapy was not significantly different
between both study groups (p=0.736). From week 2 of
(CT-)RTon, body weight loss was significantly more frequent
in concurrently treated patients than in sequentially treated
patients (p=0.005; Table 3). Also, the mean body weight loss,
both in absolute values (Table 3) as well as calculated as
percentage of total body weight (Fig. 3a), was significantly
higher in concurrently treated patients in week 2 (p=0.002),
week 3 (p=0.003) and week 4 (p=0.001) of (CT-)RT when
compared to start of (CT-)RT.
3.1.4 Grade esophagitis during concurrent and sequential
CT-RT
No significant differences were observed in the frequency of
esophagitis symptoms during the first weeks of (CT-)RT be-
tween patients treated with sequential CT-RT vs. patients
treated with concurrent CT-RT (Table 3 and Fig. 1). Because
esophagitis grade ≥2 is associated with altered nutritional
intake according to the CTCAE 3.0, longitudinal data analysis
Table 1 Study population characteristics at baseline
Retrospective Prospective
Sequential
CT-RT
Concurrent
CT-RT
Concurrent
CT-RT
Number of patients 92 102 9
Age (years)
Mean±SDa 65.8±9.4* 61.5±8.6* 56.9±10.3
Range 42–83 40–80 38–73
Gender (n (%))
Male 61 (66 %) 64 (63 %) 6 (67 %)
Female 31 (34 %) 38 (37 %) 3 (33 %)
Body weight at diagnosis (kg)
Mean±SD 73.7±15.4 72.8±13.6 70.9±14.1
Reported body weight loss in 6 months prior to diagnosis
(% of total body weight)
Mean±SD 6.42±7.34 4.65±5.95 3.4±5.7
Histology/cytology (n (%))
Adenocarcinoma 10 (10.9 %) 22 (21.6 %) 4 (44.4 %)
Squamous cell 25 (27.2 %) 22 (21.6 %) 3 (33.3 %)
Large cell 44 (47.8 %) 39 (38.2 %) 0 (00.0 %)
Not otherwise specified 13 (14.1 %) 19 (18.6 %) 2 (22.2 %)
Stage TNMb (n (%))
IIIA 31 (33.7 %) 31 (30.4 %) 5 (55.6 %)
IIIB 61 (66.3 %) 71 (69.6 %) 3 (33.3 %)
IV 00 (00.0 %) 00 (00.0 %) 1 (11.1 %)
Smoking (n (%))
Current cigarette smoker 35 (38.0 %) 43 (42.2 %) 2 (22.2 %)
Former cigarette smoker 49 (53.3 %) 55 (53.9 %) 7 (77.8 %)
Never smoker 8 (8.7 %) 4 (4.0 %) 0 (00.0 %)
*P<0.05 retrospective data, significant difference between sequential and
concurrent treated patients (Independent sample T test or Pearson chi-
square test)
aMean±standard deviation (SD)
bAccording to tumor-node-metastasis (TNM) International Staging Sys-
tem for Lung Cancer
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by means of a linear mixed model was performed to assess
whether or not the observed body weight loss during concur-
rent CT-RT was associated with esophagitis grade ≥2. Asso-
ciations between body weight loss and grade ≥2 esophagitis
were tested in two separate models, one for patients treated
with sequential and one for patients treated with concurrent
CT-RT. BMI was used in these models to calculate associa-
tions between grade ≥2 esophagitis and body weight loss
Table 2 Treatment
characteristics
*P<0.05 retrospective data, sig-
nificant difference between se-
quential and concurrent treated
patients (independent sample T
test or Pearson chi-square test)
Retrospective Prospective
Sequential
CT-RT
Concurrent
CT-RT
Concurrent
CT-RT
Number induction chemotherapy cycles (n (%)) n=88 n=85 n=9
0 0 (0.0 %)* 0 (0.00 %)* 3 (33.3 %)
1 4 (4.5 %)* 51 (60.0 %)* 0 (0.00 %)
2 4 (4.5 %)* 21 (24.7 %)* 6 (66.7 %)
3 79 (89.8 %)* 12 (14.1 %)* 0 (0.00 %)
4 1 (1.1 %)* 1 (1.2 %)* 0 (0.00 %)
Type induction chemotherapy (n (%)) n=85 n=84 n=9
Carboplatin–gemcitabine 49 (57.6 %) 44 (52.4 %) 0 (0.0 %)
Carboplatin–paclitaxel 1 (1.2 %) 0 (0 %) 0 (0.0 %)
Carboplatin–docetaxel 3 (3.5 %) 0 (0 %) 0 (0.0 %)
Carboplatin–etoposide 0 (0 %) 1 (1.2 %) 0 (0.0 %)
Cisplatin–gemcitabine 23 (27.1 %) 25 (29.8 %) 0 (00.0 %)
Cisplatin–vinorelbine 6 (7.1 %) 2 (2.4 %) 4 (44.4 %)
Cisplatin–paclitaxel 1 (1.2 %) 4 (4.8 %) 0 (00.0 %)
Cisplatin–etoposide 2 (2.4 %) 5 (6.0 %) 5 (55.6 %)
Number of concurrent chemotherapy cycles (n%) n=87 n=9
1 51 (60.0 %) 1 (6.7 %)
2 21 (24.7 %) 14 (93.3 %)
3 12 (14.1 %) 0 (0.0 %)
4 1 (1.2 %) 0 (0.0 %)
Type concurrent chemotherapy (n (%)) n=87 n=9
Cisplatin–vinorelbine 54 (62.1 %) 4 (44.4 %)
Cisplatin–etoposide 23 (26.4 %) 5 (55.6 %)
Cisplatin–vinorelbine–cetuximab 6 (6.9 %) 0 (0.00 %)
Carboplatin–etoposide 3 (3.4 %) 0 (0.0 %)
Carboplatin–paclitaxel 1 (1.1 %) 0 (0.0 %)
Treatment time RT (days)
Mean±SD 23±6 31±7* 33±5
Range 7–41 14–52 26–41
Total dose RT (Gy)
Mean±SD 59.2±10.8 61.4±6.7 64.3±6.6
Range 20–79 45–69 53 – 69
Mean lung dose (Gy)
Mean±SD 15.3±3.8 15.6±4.6 19.2±1.2
Range 5–21 4–29 26–41
Mean esophageal dose (Gy)
Mean±SD 24.8±10.1 24.7±9.2 30.6±9.5
Range 5–49 4–43 14.6–45.90
Max spinal cord dose (Gy)
Mean±SD 45.6±11.0 44.0±12.1 44.4±9.6
Range 16–55 9–56 22.0–53.3
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Table 3 Body weight changes and grade esophagitis prior and during (CT-)RT
Retrospective Prospective
Sequential CT-RT Concurrent CT-RT Concurrent CT-RT
Weight loss diagnosis—start (CT-)RT (kg) n=83 n=94 n=6
Mean±SDa −1.31±10.78 −0.50±3.03 −0.13±1.97
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 51 (61.4 %)* 75 (81.5 %)* 4 (66.7 %)
0–5 % loss of total body weight 17 (20.5 %)* 8 (8.7 %)* 2 (33.3 %)
≥5 % loss of total body weight 15 (18.1 %)* 9 (9.8 %)* 0 (0.00 %)
Weight loss week 1 (CT-)RT (kg) n=68 n=91
Mean±SDb 0.38±2.48 0.61±1.69
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 39 (57.4 %) 42 (46.2 %)
0–5 % loss of total body weight 26 (38.2 %) 45 (49.5 %)
≥5 % loss of total body weight 3 (4.4 %) 4 (4.4 %)
Weight loss week 2 (CT-)RTb (kg) n=71 n=94 n=9
Mean±SD 0.36±2.27* 1.58±2.2* 2.53±1.75†
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 37 (52.1 %)* 27 (28.7 %) 1 (11.1 %)
0–5 % loss of total body weight 29 (40.8 %)* 50 (53.2 %) 6 (66.7 %)
≥5 % loss of total body weight 5 (7.0 %)* 17 (18.1 %) 2 (22.2 %)
Weight loss week 3 (CT-)RT (kg) n=65 n=87 n=9
Mean±SD 0.54±2.21* 1.95±2.67* 4.07±3.07†
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 31(47.7 %)* 23 (26.4 %)* 1 (11.1 %)
0–5 % loss of total body weight 29 (44.6 %)* 47 (54.0 %)* 3 (33.3 %)
≥5 % loss of total body weight 5 (7.7 %)* 17 (19.5 %)* 5 (55.6 %)
Weight loss week 4 (CT-)RT (kg) n=29 n=71
Mean±SD 0.22±2.02* 2.56±3.36*
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 17 (60.7 %)* 17 (23.9 %)*
0–5 % loss of total body weight 9 (32.1 %)* 33 (46.5 %)*
≥5 % loss of total body weight 2 (7.1 %)* 21(29.6 %)*
Weight loss week 5 (CT-)RT (kg) n=9
Mean±SD 5.62±2.43†
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 2 (22.2 %)
0–5 % loss of total body weight 0 (0.00 %)
≥5 % loss of total body weight 7 (77.8 %)
Weight loss week 4 post (CT-)RT (kg) n=9
Mean±SD 4.41±3.11†
Number of patients losing weight (n (%)):
≤0 % loss of total body weight 1 (11.1 %)
0–5 % loss of total body weight 2 (22.2 %)
≥5 % loss of total body weight 6 (66.7 %)
Grade esophagitis week 1 RT (n (%)) n=74 n=86
< 2 73 (98.7 %) 81 (94.2 %)
≥ 2 1 (1.4 %) 5 (5.8 %)
Grade esophagitis week 2 RT (n (%)) n=79 n=85 n=9
<2 71(89.9 %) 77 (90.6 %) 7 (77.8 %)
≥2 8 (10.1 %) 8 (9.4 %) 2 (22.2 %)
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independent of height. No significant associations were ob-
served between body weight loss and esophagitis grade ≥2 in
the first 3 weeks of concurrent CT-RT (estimated effect=0.47,
95 % C.I.=−0.03–0.49, p=0.096), while significant associa-
tions were observed between body weight loss and esophagi-
tis grade ≥2 in patients treated with sequential therapy (esti-
mated effect=0.55, 95 % C.I.=0.28–0.82, p<0.001). In con-
currently treated patients, significant associations were ob-
served between decreases in BMI and duration of treatment
(estimated effect week 2=0.28, 95 % C.I.=0.14–0.43,
p<0.001; estimated effect week 3=0.39, 95 % C.I.=0.16–
0.61, p=0.001).
3.2 Prospective study
3.2.1 Study population characteristics
Baseline characteristics of the prospective validation group
are shown in Table 1.
3.2.2 Treatment characteristics
Treatment characteristics are depicted in Table 2. Most
patients (n=6) received one cycle of induction CT. The
other patients did not receive any induction therapy
(n=3). The type induction chemotherapy as well as the
concurrent CT consisted of cisplatin combined with
either vinorelbine (44 %) or etoposide (56 %). Patients
received two cycles of cisplatin-based concurrent CT.
Total concurrent radiation dose was 64.3±6.6 Gy (range
53–69).
3.2.3 Body weight loss during concurrent CT-RT
Data on body weight in the prospective cohort are shown in
Fig. 3b and Table 3. Body weight remained relatively stable
between diagnosis and start of concurrent CT-RT. As Fig. 3b
indicates, body weight loss started early after initiation of
therapy (p=0.002) and the body weight reached its lowest
level at the end of concurrent CT-RT (p<0.001). In the 4weeks
following CT-RT, body weight partly recovered but was still
significantly lower than the body weight at diagnosis
(p=0.003).
3.2.4 Grade esophagitis and nutritional intake
during concurrent CT-RT
In Table 3, it can be observed that the number of patients
in the prospective analysis suffering from grade esophagi-
tis that interferes with nutritional intake (grade ≥2) is low
at 2 weeks after initiation of concurrent CT-RT (∼20 %)
and increases in the later weeks of treatment (44 % in
week 3 and 75 % in week 5). As in the retrospective
analysis, the number of patients losing weight was consis-
tently higher than the percentage of patients having grade
esophagitis ≥2 (Table 3).
Table 3 (continued)
Retrospective Prospective
Sequential CT-RT Concurrent CT-RT Concurrent CT-RT
Grade esophagitis week 3 RT (n (%)) n=72 n=81 n=9
<2 48 (66.6 %) 53 (65.4 %) 5 (55.6 %)
≥2 24(33.3 %) 28(34.5 %) 4 (44.4 %)
Grade esophagitis week 4 RT (n (%)) n=31 n=66
<2 22 (71.0 %) 43 (65.2 %)
≥2 9 (29.0 %) 23 (34.8 %)
Grade esophagitis week 5 RT (n (%)) n=8
<2 2 (25 %)
≥2 6 (75 %)
Grade esophagitis week 4 post RT (n (%)) n=12
<2 8 (88.9 %)
≥2 1 (11.1 %)
*P<0.05 in retrospective study, comparison between sequential and concurrent treated patients (independent sample T test or Pearson chi-square test)
†P<0.05 in prospective study, comparison between body weight at a specific time point compared to body weight at diagnosis (paired sample T test)
aMean±standard deviation (SD)
b In the retrospective cohort, body weight loss during (CT-)RT is depicted relative to body weight at start of (CT-)RT. In the prospective cohort, the body
weight is depicted relative to diagnosis
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Total dietary intake remained relatively stable until
week 3 of CT-RT, albeit that the proportion of calories
consumed from nutritional support was already signifi-
cantly increased and the proportion of calorie consump-
tion from regular diet was already decreased in week 3
of CT-RT (Fig. 4a). Despite continuation of nutritional
support, total calorie consumption further decreased to
about -15 % at week 5 of CT-RT (statistically not
significant from start of treatment; Fig. 4a). After
4 weeks of follow up, total calorie intake was compa-
rable to the dietary intake at diagnosis, though some
patients still partly relied on supplemental nutrition. The
findings in Fig. 4b, c indicated that macronutrient intake
did not significantly alter during concurrent CT-RT, i.e.
total carbohydrate, fat and protein intake (per kg body
weight) was not significantly decreased during concur-
rent CT-RT (Fig. 4c).
3.2.5 Physical performance during concurrent CT-RT
Patients demonstrated a significant decline in muscle strength in
the first weeks of concurrent CT-RT (Fig. 5a). For quadriceps
muscle, the strength declined immediately after initiation of con-
current CT-RT and reached its minimum at week 2 of concurrent
CT-RT (p=0.042; Fig. 5a). For handgrip strength, the decline also
started at initiation of concurrent CT-RT but the lowest muscle
strength was observed at week 3 of CT-RT (p=0.002; Fig. 5a).
Both hand and quadriceps muscle strength improved in the
4weeks following concurrent CT-RTand nearly reached the level
of muscle strength at diagnosis at that time point.
In a similar pattern, global health score was decreased (p=
0.024) and fatigue score was increased (p=0.012) in the first
weeks of concurrent CT-RT. Both global health and fatigue
score improved in the 4 weeks following concurrent CT-RT
(global health: p=0.438, fatigue score: p=0.200; Fig. 5b).
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4 Discussion
In order to provide optimal care to patients being treat-
ed with concurrent CT-RT for NSCLC, the course of
treatment-induced weight loss and its dependence on the
most important acute dose-limiting side effect, i.e.
esophagitis, needs to be determined. It is believed that
weight loss and radiation-esophagitis are causally linked
because esophagitis can lead to decreased dietary intake
and subsequently, to loss of body weight [24]. However,
no data on the incidence and pattern of weight loss or
its association with treatment-induced esophagitis is
available in patients treated with concurrent CT-RT for
locally advanced NSCLC.
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mentation or tube feeding). b Changes in dietary carbohydrate (grams)
and fat (grams) intake (oral intake and supportive nutrition). cChanges in
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In a large retrospective cohort in which patients treated
with concurrent CT-RT for locally advanced NSCLC were
compared to patients treated with sequential CT-RT, we show
that loss of body weight is a common systemic complication
of concurrent CT-RT, starts early after initiation of treatment
and surprisingly and is independent of treatment-induced
esophagitis in the first weeks of CT-RT. These data on early
body weight loss were confirmed in a prospective validation
study, i.e. body weight loss was also observed during the first
3 weeks of concurrent CT-RT in the prospective study popu-
lation, while the number of patients suffering from grade ≥2
esophagitis was still low at that time and importantly, total
caloric intake was not decreased. In addition, no correlations
were found between weight loss and esophagitis until week 3
of concurrent CT-RT in the prospective cohort (data not
shown). Combined, these findings suggest that processes dif-
ferent from esophagitis-induced nutritional intake problems
may contribute to “early” body weight loss during concurrent
CT-RT. The loss of body weight despite stable energy intake
suggests that energy needs are increased, i.e. dysbalance be-
tween energy intake and energy expenditure leads to an ener-
gy deficit and subsequently, weight loss.
The observations in the prospective dataset further indicate
that body weight progressively deteriorates from week 3 to 5
of concurrent CT-RT, together with an increase in patients
exhibiting esophagitis grade ≥2. This ‘late’ body weight loss
is accompanied by a significant decrease of spontaneous oral
intake and increased reliance on supplemental nutrition. Al-
though administration of supplemental nutrition prevents the
total calorie intake to decline significantly, administration of
supplemental nutrition is not sufficient to prevent further
progression of body weight loss.
Another important finding in the current study is that after
4 weeks of completion of concurrent CT-RT, the body weight
has not completely returned to the level at diagnosis. This,
despite the fact that some of the patients are still using sup-
plemental nutrition, indicates that body weight loss is a prob-
lem that extends over at least 2 months. Since significant body
weight loss in cancer patients has been associated with nega-
tive effects on therapy response, survival as well physical as
emotional wellbeing [8], the weight loss during and following
concurrent CT-RT requires intense management to prevent
these negative consequences.
Our observations that body weight loss occurs frequently
during concurrent administration of CT-RTare consistent with
literature on body weight changes in concurrent CT-RT treat-
ment regimens in other malignancies. Several studies in head
and neck cancer show a decrease in body weight during
concurrent CT-RT starting from the first week on and continu-
ing in the weeks after concurrent CT-RT [13, 19]. These
changes in body weight are also addressed in the Clinical
Practice Guideline of the American Society of Clinical On-
cology (ASCO) for Laryngeal Cancer [4]. In addition,
comparison between radiation treatment alone and concurrent
CT-RT in cervical cancer patients showed increased body
weight loss during concurrent CT-RT [14]. However, none
of these studies have addressed the etiology or systemic
effects of this treatment-related body weight loss.
An observation in the current study that could be of impor-
tance for optimization of patient care is that the ‘early’ weight
loss during concurrent CT-RT is accompanied by a significant
decline in muscle strength. As muscle strength strongly corre-
lates with muscle mass, it is possible that the early weight loss
originates from a disturbed muscle protein turnover and subse-
quent loss of muscle mass, i.e. the balance between muscle
protein synthesis and degradation is disturbed in favor of pro-
tein degradation. Undergoing the aggressive concurrent CT-RT
treatment regimen may increase energy needs, which could
induce catabolism and deplete muscle mass. Therefore, in-
creased energy needs require adequate balancing by nutritional
intake to maintain muscle mass. Yet, not only energy balance
should be maintained but also specific attention is warranted to
the role of dietary protein intake, as this can maintain muscle
mass by stimulation of protein synthesis. However, the recom-
mended protein intake between 1.2 and 1.5 g/kg body weight
was not reached during the concurrent treatment regimen [15,
25], which indicates that more aggressive supplementation of
dietary protein is needed.More precisely, provision of branched
chain amino acids (BCAA) might by indicated, since BCAA’s
can stimulate muscle protein synthesis downstream of muscle
anabolic integrator Akt [23] and we recently reported an im-
pairment in protein synthesis signaling at the level of Akt (as
part of the anabolic PI3K/Akt/mTOR pathway) in muscle of
cachectic cancer patients with NSCLC [16].
Continuation of aggressive nutritional support during the
‘late’, esophagitis-associated weight loss (weeks 3–5 of con-
current CT-RT) seems plausible, as patients are at an even
higher risk of dietary uncompensated muscle catabolism due
to decreased esophagitis-related energy intake. Therefore, it
seems conceivable to initiate aggressive nutritional support,
possibly with specific amino acid formulation from the start of
concurrent CT-RT to prevent or attenuate ‘early’ and ‘late’
weight loss associated with concurrent CT-RT. As simulta-
neous administration of exercise training or neuromuscular
electrical stimulation significantly enhances the positive ef-
fects of nutritional support onmuscle synthesis, these physical
interventions should be considered as co-intervention [2].
In conclusion, the current study shows that ‘early’ body
weight loss is a common complication of concurrent CT-RT in
patients with locally advanced NSCLC and is independent of
decreased intake due to esophagitis. This suggests that other
treatment-dependent metabolic alterations contribute to this
‘early’ weight loss. A further decline in body weight is ob-
served during the later weeks of concurrent CT-RT, when the
incidence of esophagitis increases, and body weight is still not
totally recovered after 4 weeks post treatment. Since the
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‘early’ body weight loss is accompanied by a significant
decline in muscle strength, which may implicate active catab-
olism, more supportive and early initiated nutritional interven-
tion, preferably combined with tailored exercise could be
suggested to optimize concurrent CT-RT management. The
efficacy of such interventions needs to be explored in ade-
quately designed clinical trials.
Acknowledgments The authors certify that they comply with the ethical
guidelines for authorship and publishing of the Journal of Cachexia,
Sarcopenia and Muscle (von Haehling S, Morley JE, Coats AJS, Anker
SD. Ethical guidelines for authorship and publishing in the Journal of
Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle.
2010;1:7-8).
Conflict of interest Céline M.H. Op den Kamp, Dirk K.M. De
Ruysscher, Marieke van den Heuvel, Meike Elferink, RuudM.A. Houben,
Cary J.G. Oberije, Gerben P. Bootsma, Wiel H. Geraedts, Cordula C.M.
Pitz, Ramon C. Langen, Emiel F.M.Wouters, AnnemieM.W.J. Schols, and
Anne-Marie C. Dingemans declare that they have no conflict of interest.
Sources of support No financial support was received by the authors.
The author contributions were as follows: Conception and design of
the study: Céline Op den Kamp, Dirk De Ruysscher, Annemie Schols,
Anne-Marie Dingemans.
Acquisition of data, or analysis and interpretation of data: Céline Op
den Kamp, Dirk De Ruysscher, Marieke van den Heuvel, Meike Elferink,
Ruud Houben, Cary Oberije, Gerben Bootsma, Wiel Geraedts, Cordula
Pitz, Ramon Langen, Emiel Wouters, Annemie Schols, Anne-Marie
Dingemans.
Drafting the article or revising it critically for important intellectual
content and final approval of the version to be submitted: Céline Op den
Kamp, Dirk De Ruysscher, Marieke van den Heuvel, Meike Elferink,
Ruud Houben, Cary Oberije, Gerben Bootsma, Wiel Geraedts, Cordula
Pitz, Ramon Langen, Emiel Wouters, Annemie Schols, Anne-Marie
Dingemans.
References
1. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of con-
comitant versus sequential radiochemotherapy in locally advanced
non-small-cell lung cancer. J Clin Oncol;28:2181-2190.
2. Cermak NM, Res PT, de Groot LC, van Saris WH, Loon LJ. Protein
supplementation augments the adaptive response of skeletal muscle
to resistance-type exercise training: a meta-analysis. Am J Clin Nutr.
2012;96:1454–64.
3. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a
combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.
4. Pfister DG SAL,Weinstein GS,MendenhallWM, Adelstein DJ, Ang
KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre
J-L, Leupold N, List MA, O’Malley BO, Patel S, Marshall RP,
Schwartz MA, and Wolf GT. American Society of Clinical
Oncology Clinical Practice Guideline for the Use of Larynx-
Preservation Strategies in the Treatment of Laryngeal Cancer. J
Clin Oncol. 2006;24:3693–704.
5. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent
chemotherapy and radiotherapy of locally advanced lung cancer patients:
a prospective, population-based study. Ann Oncol. 2009;20:98–102.
6. De Ruysscher D, Dehing C, Bremer RH, et al. Maximal neutropenia
during chemotherapy and radiotherapy is significantly associated
with the development of acute radiation-induced dysphagia in lung
cancer patients. Ann Oncol. 2007;18:909–16.
7. De Ruysscher D, Faivre-Finn C, Nestle U, et al. European
Organisation for Research and Treatment of Cancer recommenda-
tions for planning and delivery of high-dose, high-precision radio-
therapy for lung cancer. J Clin Oncol. 2010;28:5301–10.
8. Fearon K, Strasser F, Anker SD, et al. Definition and classification of
cancer cachexia: an international consensus. Lancet Oncol. 2011;12:
489–95.
9. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of
sequential chemoradiotherapy compared with concurrent chemora-
diotherapy in locally advanced non-small-cell lung cancer: Groupe
Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de
Pneumo-CancerologieNPC95-01 Study. J ClinOncol. 2005;23:5910–7.
10. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of
concurrent versus sequential thoracic radiotherapy in combination
with mitomycin, vindesine, and cisplatin in unresectable stage III
non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9.
11. Jain AK, Hughes RS, Sandler AB, et al. A phase II study of concur-
rent chemoradiation with weekly docetaxel, carboplatin, and radia-
tion therapy followed by consolidation chemotherapy with docetaxel
and carboplatin for locally advanced inoperable non-small cell lung
cancer (NSCLC). J Thorac Oncol. 2009;4:722–7.
12. Johnke RM, Edwards JM, Evans MJ, et al. Circulating cytokine
levels in prostate cancer patients undergoing radiation therapy: influ-
ence of neoadjuvant total androgen suppression. In Vivo. 2009;23:
827–33.
13. McRackan TR, Watkins JM, Herrin AE, et al. Effect of body mass
index on chemoradiation outcomes in head and neck cancer.
Laryngoscope. 2008;118:1180–5.
14. Ohno T, Kato S, Wakatsuki M, et al. Incidence and temporal pattern
of anorexia, diarrhea, weight loss, and leukopenia in patients with
cervical cancer treated with concurrent radiation therapy and weekly
cisplatin: comparison with radiation therapy alone. Gynecol Oncol.
2006;103:94–9.
15. Op den Kamp CM, Langen RC, Schols AM HA. Muscle atrophy in
cachexia: can dietary protein tip the balance? Curr Opin Clin Nutr
Metab Care. 2009;12:611–6.
16. Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear
transcription factor kappaB activation and protein turnover adapta-
tions in skeletal muscle of patients with progressive stages of lung
cancer cachexia. Am J Clin Nutr 2013.
17. Price KA, Azzoli CG, Gaspar LE. Chemoradiation for unresectable
stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg.
2008;20:204–9.
18. Rowell NP, O’Rourke N P. Concurrent chemoradiotherapy in non-
small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140.
19. Silver HJ, Dietrich MS, Murphy BA. Changes in body mass, energy
balance, physical function, and inflammatory state in patients with
locally advanced head and neck cancer treated with concurrent che-
moradiation after low-dose induction chemotherapy. Head Neck.
2007;29:893–900.
20. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine.
Curr Opin Clin Nutr Metab Care. 2008;11:400–7.
21. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:
381–410.
22. van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an
individualized radiation dose prescription study based on normal
tissue constraints in stages I to III non-small-cell lung cancer. J Clin
Oncol;28:1380-1386.
23. Vary TC, Lynch CJ. Nutrient signaling components controlling pro-
tein synthesis in striated muscle. J Nutr. 2007;137:1835–43.
24. Werner-Wasik M. Treatment-related esophagitis. Semin Oncol.
2005;32:S60–6.
25. Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the
elderly. Clin Nutr. 2008;27:675–84.
J Cachexia Sarcopenia Muscle (2014) 5:127–137 137
